Page last updated: 2024-08-25

rosiglitazone and amg-837

rosiglitazone has been researched along with amg-837 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belin, RM; Brooks, DA; Cannady, EA; Cardona, GR; Chen, K; Chen, Q; Chen, Y; Coffey, DS; Deeg, MA; Eessalu, TE; Ficorilli, JV; Haas, JV; Hamdouchi, C; Johnson, JT; Kahl, SD; Lineswala, JP; Ma, X; Maiti, P; Marcelo, MC; Montrose-Rafizadeh, C; Otto, KA; Patel Lewis, A; Piper, JL; Pratt, EJ; Reifel Miller, A; Sweetana, SA; Wilbur, KL; Yumibe, NP; Zink, RW1
Deng, F; Li, Y; Li, Z; Zhang, D; Zhang, L; Zhou, Z1

Other Studies

2 other study(ies) available for rosiglitazone and amg-837

ArticleYear
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Journal of medicinal chemistry, 2016, 12-22, Volume: 59, Issue:24

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Structure; Piperidines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; Spiro Compounds; Structure-Activity Relationship

2016
Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARĪ³ and PPARĪ“.
    European journal of medicinal chemistry, 2018, Nov-05, Volume: 159

    Topics: Animals; CHO Cells; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucose Tolerance Test; HEK293 Cells; Hep G2 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Mice, Obese; Models, Molecular; Molecular Structure; PPAR delta; PPAR gamma; Receptors, G-Protein-Coupled; Structure-Activity Relationship

2018